Almost at Par

It was a two-for-one sale at Par Pharmaceutical (NYSE: PRX  ) on Wednesday as the generic-drug maker released earnings for its first and second quarters. The release of earnings for the first half of the year was delayed due to restating earnings from 2006. Better late than never, I guess.

For the first six months of the year, revenues were up 9.2% over the same period last year, although like many generic-drug makers, including Dr. Reddy's Laboratories (NYSE: RDY  ) and Teva Pharmaceuticals (Nasdaq: TEVA  ) , roller-coaster earnings resulted in different results for the two quarters.

First quarter revenues were up 36% year over year due to launches of new products such as generic versions of Wyeth's (NYSE: WYE  ) Inderal, AstraZeneca's (NYSE: AZN  ) Toprol-XL, and GlaxoSmithKline's (NYSE: GSK  ) ZANTAC. Also contributing to the nice year-over-year pump in sales was a 137% increase in branded drug sales, but unfortunately, at 8%, they're a minor contributor to total revenues.

Second-quarter revenues were down 14% year over year because of strong competition, mostly against the generic version of Glaxo's Flonase, which saw sales cut by 35% as more generic-drug makers launched versions of the product.

Par is expecting even more generic competition in the fourth quarter of 2007, but fortunately it's filed 10 Abbreviated New Drug Applications this year, so there are new product launches in Par's future.

Given the solid first half, management bumped up its expected earnings for the year by $0.40 to $1.35 to $1.50 per share. With one month left in the year, we hope that estimate is accurate.

We should know fairly soon since Par expects to have Q3 results announced "at the earliest practical date" and to be current by the end of the year.

More Foolish pharma:


Read/Post Comments (0) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 540725, ~/Articles/ArticleHandler.aspx, 9/3/2014 1:00:41 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 3 hours ago Sponsored by:
DOW 17,067.56 -30.89 -0.18%
S&P 500 2,002.28 -1.09 -0.05%
NASD 4,598.19 17.92 0.39%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

12/31/1969 7:00 PM
PRX.DL2 $0.00 Down +0.00 +0.00%
Par Pharmaceutical… CAPS Rating: ***
AZN $74.64 Down -1.37 -1.80%
AstraZeneca plc (A… CAPS Rating: ***
GSK $48.29 Down -0.81 -1.65%
GlaxoSmithKline CAPS Rating: ****
RDY $48.93 Down -0.08 -0.16%
Dr. Reddy's Labora… CAPS Rating: ****
TEVA $52.14 Down -0.38 -0.72%
Teva Pharmaceutica… CAPS Rating: *****
WYE.DL $0.00 Down +0.00 +0.00%
Wyeth CAPS Rating: ***

Advertisement